<DOC>
	<DOC>NCT01692925</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body) of four lots of turoctocog alfa (a human recombinant coagulation factor VIII (FVIII)) in subjects with haemophilia A.</brief_summary>
	<brief_title>Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtained before any trialrelated activities. Trialrelated activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial Male subjects with the diagnosis of severe haemophilia A (FVIII&lt;1%) from age 18 years Documented history of at least 150 exposure days to any other FVIII products (prevention or treatment of bleeds) Immunocompetent (HIV (Human Immunodeficiency Virus) positive subjects should have CD4+ (Cluster of differentiation 4; a glycoprotein expressed on the surface) lymphocyte count &gt;200/microL) Detectable inhibitors to FVIII (above or equal to 0.6 Bethesda Units (BU)) History of FVIII inhibitors Severe current hepatic dysfunction or severe hepatic disease during the last 12 months Known or suspected allergy to trial product (FVIII) or related products Subjects receiving immune modulating medication or immune tolerance induction (ITI) regimens Body mass index (BMI) above 30 kg/m^2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>